(Reuters) – Drugmaker Eli Lilly and Co will acquire genetic medicine developer Akouos Inc in a cash deal worth about $487 million.
Lilly will also pay Akouos’ shareholders an additional amount of about $610 million contingent on certain events related to its trials.
(Reporting by Leroy Leo in Bengaluru; Editing by Shinjini Ganguli)
